VANDA PHARMACEUTICALS INC
NASDAQ: VNDA (Vanda Pharmaceuticals Inc.)
Last update: 21 minutes ago3.88
0.09 (2.37%)
| Previous Close | 3.79 |
| Volume | 1,902,445 |
| Price / Sales | 0.990 |
| Price / Book | 1.15 |
| 52 Weeks Range |
| Profit Margin | -21.98% |
| Operating Margin (TTM) | -81.99% |
| Diluted EPS (TTM) | -0.760 |
| Quarterly Revenue Growth (YOY) | 5.40% |
| Total Debt/Equity (MRQ) | 2.30% |
| Current Ratio (MRQ) | 3.92 |
| Operating Cash Flow (TTM) | -56.47 M |
| Levered Free Cash Flow (TTM) | -41.71 M |
| Return on Assets (TTM) | -7.05% |
| Return on Equity (TTM) | -8.39% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Vanda Pharmaceuticals Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 2.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | 0.0 |
| Macro Environment | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.51 |
Select this tab to load the latest available analysis.
|
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 7.16% |
| % Held by Institutions | 78.96% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Renaissance Technologies Llc | 30 Jun 2026 | 3,441,361 |
| Aigh Capital Management Llc | 30 Sep 2026 | 2,250,000 |
| Acadian Asset Management Llc | 30 Jun 2026 | 1,918,063 |
| Two Sigma Investments, Lp | 30 Jun 2026 | 1,349,072 |
| Jacobs Levy Equity Management, Inc | 30 Jun 2026 | 1,213,326 |
| Krensavage Asset Management, Llc | 30 Jun 2026 | 1,180,388 |
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |